인쇄하기
취소

ALK NSCLC treatment, ‘Zykadia’ will be applied for insurance benefit

Published: 2016-07-25 15:35:32
Updated: 2016-07-25 15:35:32

As approved in the health insurance benefit, another ALK(Anaplastic Lymphoma Kinase) positive non-small cell lung cancer treatment can now be clinically used.

In the ‘Announced Amendment on Drugs Prescribed for Cancer Patients’ recently revealed by the Health Insurance Review & Assessment Service, the health insurance standard of the Novartis’ ALK targeted therapy, ‘Zykadia(generic name: cerit...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.